Jérôme Rey

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 347 citations

Pharmacy, Hematology, Pharmacotherapy +5

Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases

Benoît Bareau, Jérôme Rey, M. Hamidou et al. · Haematologica · 2010 · 216 citations · Full text

Medicine, Hematology, Pathology +12

Mutation analysis of <i>ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12,</i> and <i>TET2</i> in myeloproliferative neoplasms

Mandy Brecqueville, Jérôme Rey, François Bertucci et al. · Genes Chromosomes and Cancer · 2012 · 153 citations

Medicine, Genetics, Molecular Genetics +17

A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

Norbert Vey, Lionel Karlin, Sophie Sadot‐Lebouvier et al. · Oncotarget · 2018 · 136 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients

Florent Malard, Anne Vekhoff, Simona Lapusan et al. · Nature Communications · 2021 · 94 citations · Full text

Life Sciences, Microbiology, Oncology +16